首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

单株抗体市场规模、份额和成长分析（按来源、适应症、生产类型、应用、给药途径、最终用途和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897250

单株抗体市场规模、份额和成长分析（按来源、适应症、生产类型、应用、给药途径、最终用途和地区划分）－2026-2033年产业预测

Monoclonal Antibodies Market Size, Share, and Growth Analysis, By Source Type, By Indication, By Production Type, By Application, By Route of Administration, By End-Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 211 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球单株抗体市场规模将达到 2,352.7 亿美元，到 2025 年将达到 2,623.2 亿美元，到 2033 年将达到 6,266.6 亿美元，预测期（2026-2033 年）的复合年增长率为 11.5%。

生物製药，尤其是单株抗体（mAb）的需求，主要受癌症、心血管疾病和自体免疫疾病等慢性疾病日益普遍的驱动。预计这一趋势将推动单株抗体市场显着成长。由于单株抗体已成为标靶治疗的关键，并能有效中和病原体，因此逐渐获得患者和医疗专业人员的认可。主要企业正积极研发促销单株抗体疗法。合作，例如致力于提高癌症治疗效率和开发神经退化性疾病药物的合作项目，对于开拓新的机会至关重要。这些努力正在推动单株抗体领域的发展，旨在扩大各种慢性疾病的治疗选择，并改善患者照护效果。

全球单株抗体市场驱动因素

癌症和自体免疫疾病等慢性病的日益流行，正显着推动全球单株抗体市场的成长。随着人口老化和生活方式相关健康挑战的增多，对标靶治疗（尤其是单株抗体）的需求持续上升。这项转变促使製药公司加大对创新单株抗体疗法研发的投入。精准医疗的日益普及进一步凸显了对有效标靶治疗的需求，促使各公司推动这一细分市场的发展，以满足对先进治疗方案日益增长的需求。

限制全球单株抗体市场的因素

全球单株抗体市场面临的一大障碍是单株抗体研发和生产成本高。生产这些疗法需要复杂而漫长的过程，包括昂贵的检测和遵守监管标准，这些都导致了高昂的整体成本。这种经济负担会阻碍小型公司进入市场，并限制竞争和创新。此外，高昂的价格往往使患者无法获得这些先进疗法，这可能会阻碍整个单株抗体市场的扩张和潜力。这些因素共同构成了该产业成长面临的重大挑战。

全球单株抗体市场趋势

全球单株抗体市场正经历变革性趋势：现有单株抗体专利到期推动生物相似药的崛起。这项转变使得更具成本效益的替代疗法得以引入，既扩大了患者的用药范围，也提高了製药公司的盈利。生物相似药日益增长的市场接受度预计将改变市场动态，加剧单株抗体疗法领域的竞争，并推动其进一步创新。这一趋势不仅凸显了治疗方案可负担性的重要性，也展现了透过更广泛的治疗选择来改善患者预后的潜力。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

F. Hoffmann-La Roche Ltd（Switzerland）
Johnson & Johnson（USA）
Merck & Co., Inc.（USA）
AbbVie Inc.（USA）
Amgen Inc.（USA）
Novartis AG（Switzerland）
Bristol Myers Squibb Company（USA）
Eli Lilly and Company（USA）
Regeneron Pharmaceuticals Inc.（USA）
Biogen Inc.（USA）
UCB SA（Belgium）
Takeda Pharmaceutical Company Limited（Japan）
AstraZeneca PLC（UK）
GlaxoSmithKline plc（GSK）（UK）
Bayer AG（Germany）
Daiichi Sankyo Company, Limited（Japan）
Boehringer Ingelheim International GmbH（Germany）
Y-mAbs Therapeutics Inc.（USA）
Teva Pharmaceutical Industries Ltd.（Israel）

结论与建议

简介目录

Product Code: SQMIG35H2248

Global Monoclonal Antibodies Market size was valued at USD 235.27 Billion in 2024 and is poised to grow from USD 262.32 Billion in 2025 to USD 626.66 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The demand for biologics, particularly monoclonal antibodies (mAbs), is significantly driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular issues, and autoimmune disorders. Consequently, this trend positions the Monoclonal Antibodies Market for substantial growth. Awareness among patients and healthcare professionals is rising as mAbs become integral in targeted treatments, effectively neutralizing disease-causing agents. Leading companies within the industry are actively engaged in advancing and marketing mAb therapies. Collaborative efforts, such as partnerships focused on enhancing production for cancer treatment and developing drugs for neurodegenerative diseases, are pivotal in unlocking new opportunities. These initiatives are geared toward enhancing treatment options and improving patient care outcomes for a wide array of chronic conditions, thereby driving the mAbs sector forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibodies Market Segments Analysis

Global Monoclonal Antibodies Market is segmented by Source Type, Indication, Production Type, Application, Route of Administration, End-Use and region. Based on Source Type, the market is segmented into Murine, Chimeric, Humanized, Human and Others. Based on Indication, the market is segmented into Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases and Others. Based on Production Type, the market is segmented into In Vivo and In Vitro. Based on Application, the market is segmented intoOncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intravitreal and Others. Based on End-Use, the market is segmented into Hospitals, Specialty Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Monoclonal Antibodies Market

The escalating prevalence of chronic diseases like cancer and autoimmune disorders significantly fuels the growth of the Global Monoclonal Antibodies market. As populations age and lifestyle-related health challenges become more common, the demand for targeted therapies, particularly monoclonal antibodies, continues to rise. This shift has prompted pharmaceutical companies to invest heavily in the research and development of innovative monoclonal antibody-based treatments. The increasing focus on precision medicine further amplifies the need for effective targeted therapies, driving advancements in this market segment as companies seek to meet the growing demand for advanced treatment options.

Restraints in the Global Monoclonal Antibodies Market

A significant barrier in the Global Monoclonal Antibodies market is the substantial cost associated with the development and production of monoclonal antibodies. The complex and lengthy processes required to produce these therapies, which include expensive testing and adherence to regulatory standards, contribute to high overall expenses. These financial burdens can deter smaller companies from entering the market, limiting competition and innovation. Additionally, the high prices often restrict patient access to these advanced treatments, which could hinder the overall expansion and potential of the Monoclonal Antibodies market. This combination of factors presents a notable challenge for growth in the sector.

Market Trends of the Global Monoclonal Antibodies Market

The Global Monoclonal Antibodies market is witnessing a transformative trend with the rise of biosimilars, driven by the expiration of patents on established monoclonal antibodies. This shift enables the introduction of cost-effective alternatives, facilitating broader access for patients while enhancing profitability for pharmaceutical companies. As biosimilars gain acceptance, the market dynamics are expected to evolve, fostering increased competition and stimulating further innovation in the development of monoclonal therapies. This trend not only underscores the importance of affordability in treatment options but also highlights the potential for enhanced patient outcomes through a wider array of therapeutic choices.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Monoclonal Antibodies Market Size by Source Type & CAGR (2026-2033)

Market Overview
Murine
Chimeric
Humanized
Human
Others

Global Monoclonal Antibodies Market Size by Indication & CAGR (2026-2033)

Market Overview
Cancer
- Breast cancer
- Colorectal cancer
- Lung cancer
- Ovarian cancer
- Others
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others

Global Monoclonal Antibodies Market Size by Production Type & CAGR (2026-2033)

Market Overview
In Vivo
In Vitro

Global Monoclonal Antibodies Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others

Global Monoclonal Antibodies Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous
Subcutaneous
Intravitreal
Others

Global Monoclonal Antibodies Market Size by End-Use & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Centers
Others

Global Monoclonal Antibodies Market Size & CAGR (2026-2033)

North America (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- US
- Canada
Europe (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Source Type, Indication, Production Type, Application, Route of Administration, End-Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Y-mAbs Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments